Thrombosis events in Chinese patients with newly diagnosed multiple myeloma

[1]  X. Leleu,et al.  Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort , 2022, Journal of thrombosis and haemostasis : JTH.

[2]  C. Rioufol,et al.  Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study , 2021, Journal of Cancer Research and Clinical Oncology.

[3]  D. Angelini,et al.  Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study , 2020, medRxiv.

[4]  G. Morgan,et al.  Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials. , 2020, Blood.

[5]  S. Goldhaber,et al.  Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents , 2020, British journal of haematology.

[6]  M. Gavriatopoulou,et al.  Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools , 2020, Cancers.

[7]  B. Gage,et al.  Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score , 2019, American journal of hematology.

[8]  B. Gage,et al.  Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Ang Li,et al.  The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma , 2018, Annals of Hematology.

[10]  C. Bradbury,et al.  Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations , 2018, British journal of haematology.

[11]  J. Laubach,et al.  Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review , 2017, JAMA oncology.

[12]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[13]  O. Decaux,et al.  MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs , 2013, Thrombosis and Haemostasis.

[14]  Z. Cai,et al.  A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial , 2013, Journal of Hematology & Oncology.

[15]  H. Takano,et al.  A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. , 2013, Thrombosis research.

[16]  A. Khorana,et al.  Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis , 2012, Journal of thrombosis and haemostasis : JTH.

[17]  R. Pfeiffer,et al.  Thrombosis is associated with inferior survival in multiple myeloma , 2012, Haematologica.

[18]  B. Barlogie,et al.  Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis , 2012, Cancer.

[19]  G. Gal,et al.  Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis , 2011, Journal of thrombosis and haemostasis : JTH.

[20]  P. L. Bergsagel,et al.  Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. , 2010, Blood.

[21]  J. H. Lee,et al.  Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide , 2010, Annals of Hematology.

[22]  U. Mellqvist,et al.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. , 2009, Blood.

[23]  A. Falanga,et al.  Venous thromboembolism in the hematologic malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Arya,et al.  Venous thromboembolism and ethnicity , 2009, British journal of haematology.

[25]  A. Shamseddine,et al.  Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. , 2009, Thrombosis research.

[26]  U. Mellqvist,et al.  Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. , 2008, Blood.

[27]  B. Barlogie,et al.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.

[28]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[29]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[30]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[31]  M. Dimopoulos,et al.  Thalidomide and dexamethasone combination for refractory multiple myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M. Dimopoulos,et al.  Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.